Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Stephanie L. Borgland, Drew M. Neyens
Journal of Psychiatry and Neuroscience June 1, 2022 DOI: 10.1503/jpn.220090 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression LSD Serotonin |
| Keywords | Hallucinogen Clinical trial Eating disorders |
| Citations | 14 |
| Key points | There has been substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for psychiatric illnesses including substance use disorder and major depressive disorder. |
Abstract
There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid